Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib + Osimertinib in EGFRm+/MET+ NSCLC
NCT05009836Phase 3Active, not recruiting
- Sponsor
- HUTCHMED
- Start
- Sep 2021
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by HUTCHMED. Started Sep 2021; status: active, not recruiting.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05009836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009836.